

DAFTAR PUSTAKA

- Aapro, M., Y. Beguin, C. Bokemeyer, M. Dicato, P. Gascón, J. Glaspy, A. Hofmann, H. Link, T. Littlewood, H. Ludwig, A. Österborg, P. Pronzato, V. Santini, D. Schrijvers, R. Stauder, K. Jordan dan J. Herrstedt. 2018. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Annals of Oncology*. Vol. 29, No. February, h. iv96-iv110.
- Adams, H. J. A., J. M. H. De Klerk, R. Fijnheer, B. G. F. Heggelman, S. V. Dubois, R. A. J. Nievelstein dan T. C. Kwee. 2015. Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*. Vol. 15, No. 11, h. 671–679.
- Ai, L., S. Mu dan Y. Hu. 2018. Prognostic role of RDW in hematological malignancies: A systematic review and meta-analysis. *Cancer Cell International*. Vol. 18, No. 1, h. 1–8.
- Ansell, S. M. 2015. Non-Hodgkin Lymphoma: Diagnosis and Treatment. *Mayo Clinic Proceedings*. Vol. 90, No. 8, h. 1152–1163.
- Armitage, J. O., R. D. Gascoyne, M. A. Lunning dan F. Cavalli. 2017. Non-Hodgkin lymphoma. *The Lancet*. Vol. 390, No. 10091, h. 298–310.
- Blohmer, J. U., J. Dunst, L. Harrison, P. Johnston, D. Khayat, H. Ludwig, M. O’Brien, S. Van Belle dan P. Vaupel. 2005. Cancer-related anemia: Biological findings, clinical implications and impact on quality of life. *Oncology*. Vol. 68, No. SUPPL. 1, h. 12–21.
- Boehme, V., N. Schmitz, S. Zeynalova, M. Loeffler dan M. Pfreundschuh. 2009. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood*. Vol. 113, No. 17, h. 3896–3902.
- Buffett, P. 2018. Cancer-and Induced Anemia.
- Chemotherapy, C., P. Rituximab, C. With, C. Aloneelderly, P. With dan D. L. Lymphoma. 2002. CHOP Chemotherapy Plus Rituximab Compared With CHOP

- Alone In Elderly Patients With Diffuse Large-B-Cell Lymphoma. Vol. 346, No. 4, h. 235–242.
- Clark, T. G., M. J. Bradburn, S. B. Love dan D. G. Altman. 2003. Survival Analysis Part I: Basic concepts and first analyses. *British Journal of Cancer*. Vol. 89, No. 2, h. 232–238.
- Coiffier, B., C. Gisselbrecht, A. Bosly, R. Herbrecht, R. Bouabdallah, P. Morel, E. Van Den Neste, D. Bordessoule, C. Haioun, H. Tilly dan G. Salles. 2009. 10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma. *Blood*. Vol. 114, No. 22, h. 3741–3741.
- Dzis, I., O. Tomashevskaya, Y. Dzis dan Z. Korytko. 2020. Prediction of survival in non-hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and eastern cooperative oncology group performance status. *Acta Haematologica Polonica*. Vol. 51, No. 1, h. 34–41.
- Ellingsen, T. S., J. Lappégard, T. Skjelbakken, S. K. Brækkan dan J. B. Hansen. 2015. Impact of red cell distribution width on future risk of cancer and all-cause mortality among cancer patients – The Tromsø study. *Haematologica*. Vol. 100, No. 10, h. e387–e389.
- Feld, R., G. P. Bodey, V. Rodriguez dan M. Luna. 1974. Causes of death in patients with malignant lymphoma. *American Journal of the Medical Sciences*. Vol. 268, No. 2, h. 97–106.
- Gómez, H., M. Hidalgo, L. Casanova, R. Colomer, D. L. Pen, J. Otero, W. Rodríguez, C. Carracedo, H. Cortés-Funes dan C. Vallejos. 1998. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. *Journal of Clinical Oncology*. Vol. 16, No. 6, h. 2065–2069.
- Gouveia, G. R. dan J. Pereira. 2012. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. Vol. 34, No. 6, h. 447–451.
- Hardianti, M. S., S. Hasna, M. Rizki dan H. Arkananda. 2021. Anemia in Lymphoma Patients in Indonesia : The Prevalence and Predictive Anemia in Lymphoma Patients in Indonesia : The Prevalence and Predictive Factors. No. November, h. 0–7.
- Hu, L., M. Li, Y. Ding, L. Pu, J. Liu, J. Xie, M. Cabanero, J. Li, R. Xiang dan S. Xiong.

2017. Prognostic value of RDW in cancers: A systematic review and meta-analysis. *Oncotarget*. Vol. 8, No. 9, h. 16027–16035.
- Koma, Y., A. Onishi, H. Matsuoka, N. Oda, N. Yokota, Y. Matsumoto, M. Koyama, N. Okada, N. Nakashima, D. Masuya, H. Yoshimatsu dan Y. Suzuki. 2013. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. *PLoS ONE*. Vol. 8, No. 11, h. 1–7.
- Li, M., H. Xia, H. Zheng, Y. Li, J. Liu, L. Hu, J. Li, Y. Ding, L. Pu, Q. Gui, Y. Zheng, Z. Zhai dan S. Xiong. 2019. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients. *BMC Cancer*. Vol. 19, No. 1, h. 1–11.
- Ludirdja, E. P., N. M. R. A. Rena, K. Suega dan M. Bakta. 2018. Satu tahun kesintasan penderita limfoma non-hodgkin berdasarkan klasifikasi histopatologi working formulation. *Jurnal Penyakit Dalam Udayana*. Vol. 2, No. 2, h. 28–31.
- Mărginean, C. O., L. E. Meliț, E. Horvath, H. Gozar dan M. I. Chinceșan. 2018. Non-Hodgkin lymphoma, diagnostic, and prognostic particularities in children – a series of case reports and a review of the literature (CARE compliant). Vol. 97, No. 8, h. e9802.
- Mei, M., Y. Wang, W. Song dan M. Zhang. 2020. Primary causes of death in patients with non-hodgkin's lymphoma: A retrospective cohort study. *Cancer Management and Research*. Vol. 12, h. 3155–3162.
- O'Brien, M. E. R., A. Borthwick, A. Rigg, A. Leary, L. Assersohn, K. Last, S. Tan, S. Milan, D. Tait dan I. E. Smith. 2006. Mortality within 30 days of chemotherapy: A clinical governance benchmarking issue for oncology patients. *British Journal of Cancer*. Vol. 95, No. 12, h. 1632–1636.
- Periša, V., L. Zibar, J. Sinčić-Petričević, A. Knezović, I. Periša dan J. Barbić. 2015. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: A retrospective study. *Croatian Medical Journal*. Vol. 56, No. 4, h. 334–343.
- Pfreundschuh, M., E. Kuhnt, L. Trümper, A. Österborg, M. Trneny, L. Shepherd, D. S. Gill, J. Walewski, R. Pettengell, U. Jaeger, P. L. Zinzani, O. Shpilberg, S. Kvaloy, P. de Nully Brown, R. Stahel, N. Milpied, A. López-Guillermo, V. Poeschel, S.

- Grass, M. Loeffler dan N. Murawski. 2011. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. *The Lancet Oncology*. Vol. 12, No. 11, h. 1013–1022.
- Pfreundschuh, M., L. Trümper, A. Österborg, R. Pettengell, M. Trneny, K. Imrie, D. Ma, D. Gill, J. Walewski, P. L. Zinzani, R. Stahel, S. Kvaloy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo, C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt dan M. Loeffler. 2006. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncology*. Vol. 7, No. 5, h. 379–391.
- Reksodiputro, A. H. 2015. Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. *Journal of Blood Disorders & Transfusion*. Vol. 6, No. 2, h. 2–6.
- Rodgers, G. M. dan J. A. Gilreath. 2019. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. *Acta Haematologica*. Vol. 142, No. 1, h. 13–20.
- Salvagno, G. L., F. Sanchis-Gomar, A. Picanza dan G. Lippi. 2015. Red blood cell distribution width: A simple parameter with multiple clinical applications. *Critical Reviews in Clinical Laboratory Sciences*. Vol. 52, No. 2, h. 86–105.
- Schechter, A. N. 2014. Hemoglobin research and the origins of molecular medicine ASH 50th anniversary review Hemoglobin research and the origins of molecular medicine. Vol. 112, No. 10, h. 3927–3938.
- Shi, X., X. Liu, X. Li, Y. Li, D. Lu, X. Sun, Y. Li, S. Hu, Y. Zhang, X. Zhou, X. Wang, H. Chen dan X. Fang. 2021. Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. *Frontiers in Oncology*. Vol. 11, No. December, h. 1–9.
- Singh, R., S. Shaik, B. Negi, J. Rajguru, P. Patil, A. Parihar dan U. Sharma. 2020. Non-Hodgkin's lymphoma: A review. *Journal of Family Medicine and Primary Care*.

- Vol. 9, No. 4, h. 1834.
- Suchmacher, M. dan M. Geller. 2012. Study Type Determination. *Practical Biostatistics*. No. Chapter 4, h. 3–15.
- Susanibar-adaniya, S. dan S. K. Barta. 2021. Update on Diffuse large B cell lymphoma: A review. *Am J Hematol*. Vol. 96, No. 5, h. 617–629.
- Tisi, M. C., V. Bozzoli, M. Giachelia, G. Massini, B. M. Ricerca, E. Maiolo, F. D'Alo, L. M. Larocca, A. Piciocchi, H. Tjalsma, D. W. Swinkels, M. T. Voso, G. Leone dan S. Hohaus. 2014. Anemia in diffuse large B-cell non-Hodgkin lymphoma: The role of interleukin-6, hepcidin and erythropoietin. *Leukemia and Lymphoma*. Vol. 55, No. 2, h. 270–275.
- Troppan, K. T., T. Melchardt, A. Deutsch, K. Schlick, T. Stojakovic, M. D. Bullock, D. Reitz, C. Beham-Schmid, L. Weiss, D. Neureiter, K. Wenzl, R. Greil, P. Neumeister, A. Egle dan M. Pichler. 2015. The significance of pretreatment anemia in the era of R-IPi and NCCN-IPi prognostic risk assessment tools: A dual-center study in diffuse large B-cell lymphoma patients. *European Journal of Haematology*. Vol. 95, No. 6, h. 538–544.
- Winarto, D., N. M. R. A. Rena, W. L. Adnyana, T. G. Dharmayuda, K. Suega dan I. M. Bakta. 2018. Kadar hemoglobin awal sebagai faktor prognostik penderita limfoma non-hodgkin (LNH) yang menjalani kemoterapi. *Jurnal Penyakit Dalam Udayana*. Vol. 2, No. 2, h. 38–43.
- Yang, S. dan G. Berdine. 2017. The receiver operating characteristic (ROC) curve. *The Southwest Respiratory and Critical Care Chronicles*. Vol. 5, No. 19, h. 34.
- Yasmeen, T., J. Ali, K. Khan dan N. Siddiqui. 2019. Frequency and causes of anemia in lymphoma patients. *Pakistan Journal of Medical Sciences*. Vol. 35, No. 1, h. 61–65.
- Zhou, S., F. Fang, H. Chen, W. Zhang, Y. Chen, Y. Shi, Z. Zheng, Y. Ma, L. Tang, J. Feng, Y. Zhang, L. Sun, Y. Chen, B. Liang, K. Yu dan S. Jiang. 2017. Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients. *Oncotarget*. Vol. 8, No. 25, h. 40724–40731.
- Zhou, Z., L. H. Sehn, A. W. Rademaker, L. I. Gordon, A. S. Lacasce, A. Crosby-thompson, A. Vanderplas, A. D. Zelenetz, G. A. Abel, M. A. Rodriguez, A. Nademanee, M. S. Kaminski, M. S. Czuczman, M. Millenson, J. Niland, R. D.

Gascoyne, J. M. Connors, J. W. Friedberg dan J. N. Winter. 2014. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Vol. 123, No. 6, h. 837–842.



UNIVERSITAS
GADJAH MADA

**NILAI PROGNOSTIK HEMOGLOBIN DAN RED BLOOD CELL DISTRIBUTION WIDTH TERHADAP
KESINTASAN HIDUP PADA
LIMFOMA NON HODGKIN**

LIDWINA TIKA T., dr. Mardiah Suci Hardianti, Ph.d, Sp.PD, KHOM.; Dr. dr. Ibnu Purwanto, SpPD, KHOM
Universitas Gadjah Mada, 2022 | Diunduh dari <http://etd.repository.ugm.ac.id/>